Candel Therapeutics, Inc.
CADL
$12.17
-$0.43-3.41%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.15M | 6.65M | 4.93M | 4.90M | 4.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.75M | 16.28M | 15.75M | 13.21M | 11.18M |
| Operating Income | -26.75M | -16.28M | -15.75M | -13.21M | -11.18M |
| Income Before Tax | -38.91M | -8.86M | -29.50M | -11.27M | -4.80M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -38.91M | -8.86M | -29.50M | -11.27M | -4.80M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.91M | -8.86M | -29.50M | -11.27M | -4.80M |
| EBIT | -26.75M | -16.28M | -15.75M | -13.21M | -11.18M |
| EBITDA | -26.58M | -16.14M | -15.58M | -13.01M | -10.94M |
| EPS Basic | -0.52 | -0.14 | -0.54 | -0.21 | -0.09 |
| Normalized Basic EPS | -0.33 | -0.09 | -0.34 | -0.13 | -0.06 |
| EPS Diluted | -0.52 | -0.14 | -0.54 | -0.21 | -0.09 |
| Normalized Diluted EPS | -0.33 | -0.09 | -0.34 | -0.13 | -0.06 |
| Average Basic Shares Outstanding | 74.13M | 62.36M | 54.90M | 54.89M | 51.49M |
| Average Diluted Shares Outstanding | 74.13M | 62.36M | 54.90M | 54.89M | 51.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |